MBBEONE@EC2612A

BeiGene and Amgen's Bispecific Antibody Aytept Approved by NMPA for SCLC Treatment

Shanghai Pharma Holdings and BeiGene Hold Strategic Cooperation Signing Ceremony

2025 Top 10 Domestic Innovative Drug Companies Revenue Surpasses 100 Billion, BeiGene Leads Turnaround

BeiGene 2026 Q1 Earnings Soar: Net Profit Surges 178x, Revenue Breaks 10 Billion RMB Barrier

BeiGene's Sorotorac Gets FDA Accelerated Approval, Deepening BCL-2 Layout to Mitigate Single-Product Risk

BeiGene's Brukinsa Approved by FDA

BGI Q1 Profit Surges, Revenue Breaks 10 Billion Yuan

CMBC International and DBS Maintain Buy Rating for BeiGene

Citibank Raises BeiGene's US Stock Target Price to $453

Belayzhizun (BeiJing) Q1 Earnings Exceed Expectations

BeiGene Releases Q1 2026 Financial Report and Revises Financial Guidance

Beyterzelk and Amgen Authorized Products Drive First Quarter 2026 Revenue Growth for BeiGene

BeiGene Adjusts 2026 Full-Year Operating Performance Forecast

BEONE MEDICINES released FY2026 Q1 earnings on May 6 Pre-Market (BJT), actual revenue HKD 11.86 B (forecast HKD 11.26 B), actual EPS HKD 1.1755

BeiGene Secures Global Rights to Huaheng's Tri-Antibody for $20 Million

BEONE MEDICINES to release FY2026 Q1 earnings on May 6 Pre-Market (BJT), forecast revenue HKD 11.27 B

BofA Securities Notes BeiGene's Pharmaceutical Sales Growth Maintains Buy Rating

BeiGene's Wholly-Owned Subsidiary Signs Exclusive Option, License and Collaboration Agreement with Huahui Anjian

BGT Biotechnology Reports First Yearly Profit, Innovation Pharmaceuticals Reach Critical Milestone

JOLIMARK

TIMES UNI GP

APEX ACE HLDG

VPOWER GROUP

GW TIANDI

FUJING HOLDINGS

TEAMWAY INTL GP

SFSY NEW MAT

FDB HOLDINGS

KEEN OCEAN

03692

09618

89618

02423

BEKE

06160

688235

HJDD

01810

81810

HXXD

XIACY

HERO

01519

09896

MNSO

01024

81024

HKUD

0526 | Dolphin Research Focus: 🐬 Macro/Industry. 1) The US and Iran reached a framework for an MoU; Iran would reopen the Strait of Hormuz within 30 days of signing, the US would unfreeze $12bn of Iranian assets, and both sides would implement a ceasefire.This would significantly ease near-term Middle East tensions and stabilize the global energy supply chain (about 30% of crude flows through the strait). It supports a pullback in oil and a rebound in energy stocks.However, the arrangement is temporary and does not address core issues such as Iran's nuclear program. Longer-term execution remains uncertain.2) Hang Seng Indexes Company announced the results of its regular quarterly index rebalancing. ...

BEKE rolls out HK buyback shield; Xiaomi faces earnings test tonight | Daily News Recap

03033

03032

On May 22, the Hang Seng Index Company announced the results of its quarterly review, with the Hang Seng Tech Index including domestic AI model leaders Zhizhu and MINIMAX for the first time. The adjustments will be implemented after the market closes on June 5, 2026, and will take effect on June 8. The number of constituent stocks in the Hang Seng Index will increase to 93, including Jitu, China Aluminum, and BEONE MEDICINES, while the biotech index will maintain 30 constituent stocks

同壁财经

BEONE MEDICINES

CSOP HS TECH

HSTECH ETF

Hang Seng TECH Index

Hang Seng Index

Hang Seng China Enterprises Index

Hang Seng Composite Index

J&T EXPRESS-W

CHALCO

BeOne Medicines

Beigene

INSILICO

EVEREST MED

ChinaAMC Hang Seng ETF

ChinaAMC Hang Seng Technology ETF(QDII)

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Accendra Health

The Hang Seng Tech Index includes Zhizhu and MINIMAX, and the Hong Kong stock market is closed today

688271

United Imaging Healthcare showcased its full-process ecological closed-loop output at the Global Radiation Oncology Conference, with its core product uRT-linac 506c receiving CE MDR certification, marking the ecological output of high-end medical equipment in China. BeOne Medicines' Class 1 new drug BG-75202 has obtained clinical trial approval, targeting tumor resistance mechanisms and is at the forefront of the industry. These innovations reflect the technological breakthroughs and global market growth potential of Chinese medical enterprises

United Imaging Healthcare

ChinaAMC SSE STAR Biology and Medicine ETF

STAR Biology and Medicine

The leading innovative drug company frequently reports good news, with solid innovation reinforcing long-term value

Citic Securities has reaffirmed its Buy rating for BeOne Medicines Ltd (6160) as of May 12, setting a price target of HK$234.00, while the shares closed at HK$189.90. The analyst consensus for the stock is Strong Buy, with a target consensus of HK$254.33, indicating a potential upside of 33.93%. Additionally, DBS also maintains a Buy rating with a price target of HK$290.00.

Tip Ranks

CITIC SEC

CITIC Securities Co., Ltd.

Citic Securities Sticks to Its Buy Rating for BeOne Medicines Ltd (6160)

Yesterday's closing price for BeOne Medicines was HKD 190.5, with an intraday volatility of over 4%. The highest price reached HKD 191.8, while the lowest dipped to HKD 183.3, ultimately closing with a slight decline of 0.05%. The MACD daily line formed a golden cross signal above the zero axis, indicating that bullish momentum is re-accumulating in the previous upward trend, with phase buying pressure building up again. The total trading volume reached HKD 748 million, maintaining an active range as a leading stock in the biotechnology sector, with sustained investor interest. On the news front, the global biotechnology sector has recently gained continuous attention. As one of the most internationalized Chinese innovative pharmaceutical companies, BeOne Medicines' core pipelines such as PD-1 and BTK inhibitors are expected to see significant growth in overseas markets, which remains an important logic for institutional investment. Additionally, the Hong Kong stock market has recently benefited from expectations of diplomatic interactions between the U.S. and China—U.S. President Trump is scheduled to visit China from May 13 to 15, which the market interprets as a temporary easing of U.S.-China relations, likely reducing geopolitical uncertainties in the biopharmaceutical field and providing positive catalysts for companies like BeOne Medicines that have significant business in the U.S. From a technical perspective, BeOne Medicines' current stock price is operating near the 5-day and 10-day moving averages, with the short-term moving average system maintaining a bullish arrangement. Although there was significant volatility during the day, the final closing price remained stable near the opening price, indicating a temporary balance between bullish and bearish forces. After confirming the golden cross above the MACD zero axis, if the trading volume continues to stay above HKD 600 million in the following trading days, the momentum to test previous highs is expected to continue

Technical Forecast

WUXI BIO

AKESO

WuXi Biologics

Pre-market trend | BeOne Medicines (6160.HK) 5/11 bulls accumulate and close flat, is a new round of rally about to start?

In a report released yesterday, from CMBC International maintained a Buy rating on BeOne Medicines Ltd, with a price target of HK$278.85.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks In a report released on May 7, DBS also maintained a Buy rating on the stock with a HK$290.00 price target.

BeOne Medicines Ltd (6160) Gets a Buy from CMBC International

BGNE

UBS Reaffirms Their Buy Rating on BeOne Medicines Ltd (6160)

businessinsider

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

SPDR S&P Biotech

Ark Genomic Revolution ETF

UBS Reaffirms Their Buy Rating on BeOne Medicines Ltd (6160)

159316

SBIO

513120

UOB Kay Hian has reaffirmed its Buy rating for BeOne Medicines Ltd (6160), setting a price target of HK$257.00, while the stock closed at HK$188.90. The analyst consensus for BeOne Medicines is Strong Buy, with a target consensus of HK$252.79, indicating a potential upside of 33.82%. Additionally, DBS also maintains a Buy rating with a higher price target of HK$290.00.

E Fund Hang Seng SCHK Innovative Drug ETF

China Southern Hang Seng Biotech ETF(QDII)

Guotai CSI Bio-medicine ETF

ALPS Medical Breakthrough

Huaan Hang Seng Biotech ETF

E Fund CSI Biotechnology Theme ETF

Health Care Select Sector SPDR

China Merchants CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Penghua SSE STAR Biology and Medicine ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

iShares US Pharma

ICBCCS SSE STAR Biology and Medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

Tianhong CNI BIOMEDICINE ETF

VG Health

Ping An CSI Medicine and Medical Device Innovation ETF

Penghua CSI HK Connect Health Care Composite ETF

Guotai SSE STAR Brand Name Drug ETF

China Universal 800 Health Care ETF

Bosera Hang Seng Health Care ETF(QDII)

Founder Fubon CSI Medicine and Medical Device Innovation ETF

UOB Kay Hian

UOB Kay Hian Sticks to Their Buy Rating for BeOne Medicines Ltd (6160)

Today’s Key News Recap

HANSOH PHARMA

JD-SW

JD.com

JD-SWR

BEKE-W

JD HK SDR 10to1

XIAOMI-W

XIAOMI-WR

Xiaomi HK SDR 2to1

Xiaomi Corporation

Global X Video Games & Esports ETF

Miniso

KUAISHOU-W

KUAISHOU-WR

Kuaishou HK SDR 5to1

$Beigene(ONC.US)$Zai Lab(ZLAB.US)Trump administration plans to impose strict controls on Chinese pharmaceuticalsmp.weixin.qq.com/s/gihUP-...

当前环境异常，完成验证后即可继续访问。

Zai Lab

ZAI LAB

The Hang Seng Index opened higher, refreshing its nearly four-year high; Tencent's performance exceeded expectations, receiving collective bullish calls from major banks; Chip stocks strengthened on the logic of domestic substitution, with SMIC leading the gains; Ping An's stake increase in China Taiping H-shares ignited the insurance sector; Cryptocurrency concept stocks surged as Bitcoin hit a new high; In the pharmaceutical sector, Jingtai Holdings reported its first profit, rising over 11%, while East Buy saw a sudden 12% increase.

Tencent

TENCENT

TENCENT-R

Tencent HK SDR 10to1

Tencent Holdings Limited

Ping An Insurance

PING AN

PING AN-R

Ping An Ins HK SDR2to1

Ping An

SMIC

SMIC HK SDR 5to1

CPIC

CHINA TAIPING

SUNSHINE INS

Life and Health Insurance

REMEGEN

RemeGen

FI2 CSOP HSI

HUA HONG SEMI

Hua Hong

INNOCARE

InnoCare Pharma

GRANDSHORES

HORIZONROBOT-W

ZA ONLINE

BITFIRE GROUP

GUOTAI JUNAN I

XTALPI

Life Sciences Tools and Services

XL2CSOPHSTECH

Semiconductors

FL2 CSOP HSI

LINEKONG

INNOVENT BIO

OKG TECH

Interactive Media and Services

XI2CSOPHSTECH

EAST BUY

Hot Trades in Hong Kong Stocks (8.14) | Hang Seng Index Hits Four-Year High at Opening, Morgan Stanley Says Foreign Capital Accelerated Inflows into Chinese Stock Market in July

Hong Kong stocks opened high and moved higher, with technology stocks and pharmaceutical stocks rising together. The technology index rose 2.35%, Tencent Music surged more than 15% after earnings, and Alibaba rose more than 4%.

BABA-WR

Hong Kong stock hot trading (8.13)｜ Hong Kong technology stocks fully exploded, Tencent hit a four-year high, Alibaba surged over 4%

MBBEONE@EC2612A(29544.HK)

BEKE rolls out HK buyback shield; Xiaomi faces earnings test tonight | Daily News Recap

The Hang Seng Tech Index includes Zhizhu and MINIMAX, and the Hong Kong stock market is closed today

The leading innovative drug company frequently reports good news, with solid innovation reinforcing long-term value

Citic Securities Sticks to Its Buy Rating for BeOne Medicines Ltd (6160)

Pre-market trend | BeOne Medicines (6160.HK) 5/11 bulls accumulate and close flat, is a new round of rally about to start?